We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > magrolimab

News List

Gilead gets FDA breakthrough therapy status for magrolimab in MDS pharmaceutical-business-review
September 18, 2020
Gilead Sciences has been given breakthrough therapy designation for magrolimab from the US Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome (MDS) in newly diagnosed patients.
Gilead to Acquire Immuno-Oncology Company Forty Seven for $4.9 Billion biospace
March 04, 2020
Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards.
Gilead to Acquire Forty Seven for $4.9B contractpharma
March 03, 2020
Will gain lead product candidate magrolimab in clinical development for the treatment of several cancers.